Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has shared an announcement.
Recce Pharmaceuticals has secured a key Brazilian patent for its RECCE 327 and RECCE 529 anti-infective compounds, extending protection to 2041 and covering their preparation, broad therapeutic use against multiple infections, and diverse delivery formats including oral, inhalation, injectable, and topical routes. The grant, Recce’s seventh in its Family 4 portfolio, strengthens its intellectual property position in Brazil, South America’s largest antibiotic market, underpinning its strategy to address the growing threat of antibiotic-resistant superbugs while expanding protection across leading antibiotic markets worldwide.
The most recent analyst rating on (AU:RCE) stock is a Sell with a A$0.50 price target. To see the full list of analyst forecasts on Recce Pharmaceuticals Ltd. stock, see the AU:RCE Stock Forecast page.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd. is an Australia-based biotechnology company developing a new class of synthetic anti-infective drugs. Its lead candidates, RECCE 327 and RECCE 529, target a broad range of bacterial and viral infections, with a strategic focus on major global antibiotic markets.
Average Trading Volume: 105,782
Technical Sentiment Signal: Buy
Current Market Cap: A$154.7M
For a thorough assessment of RCE stock, go to TipRanks’ Stock Analysis page.